Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead’s GS9450 falters in hepatitis C, but HIV combo component advances

This article was originally published in Scrip

Executive Summary

Gilead has unexpectedly halted a Phase II trial of its investigational caspase inhibitor GS9450 in patients with chronic hepatitis C due to safety concerns. The company tried to temper the unexpected news by emphasizing that Johnson & Johnson's NNRTI TMC278 (rilpivirine hydrochloride), which is being developed in part to be combined with Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate), met its primary endpoints in two pivotal Phase III HIV trials, but analysts were divided on the implications of this development.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts